Prof. Dollar retweeted
Replying to @RxRegA
What was far more troubling was a sitting CBER director speaking anonymously to reporters to publicly discredit an investigational Huntington’s therapy under his own agency’s review.
Calling AMT-130 a “failed product,” disputing prior regulatory commitments, and dismissing the concerns of families facing an irreversible, fatal disease deserved public scrutiny.
@adamfeuerstein did his job. Federal regulators wielding extraordinary power over patients’ futures should not be shielded from public scrutiny by anonymity. The public deserves transparency and accountability, not regulatory interference behind closed doors.
Prof. Dollar retweeted
🚨🗣️Ivan Jovanović on Netherlands’ incredible 7-0 humiliation of Greece:
“I have been involved in football for many years, but honestly, I have never seen anything like this in my life.
The way the Netherlands played was shocking. We couldn’t even get close to the ball. Every time we tried to press, they had already found another passing option. It felt like we were always two steps behind.
Xavi genuinely surprised me. His tactical ideas were something else. The positioning, the movement, the way they controlled every area of the pitch. It was unbelievable.
At some point, I stopped trying to understand how we could get the ball back and started watching how they were moving it.
What impressed me most was how comfortable every player looked. Nobody was rushing, nobody was panicking. They knew exactly where their teammates would be before the ball even arrived.
Even when we tried to change our pressing structure, they found solutions immediately. It was like they had already anticipated everything we wanted to do.
I’ve seen great teams before, but this was different.
For once in my life, I watched the Netherlands play football like prime Barcelona. The confidence, the possession, the intelligence and the constant movement. Everything was there.
I actually want to sit down with Xavi and ask him more about this style. I want to understand how he gets his players to execute these movements so perfectly. There is clearly something special happening in that dressing room.
I also have to give credit to the players. You can have the best tactical instructions in the world, but executing them at that level requires extraordinary intelligence and understanding.
Because tonight, we weren’t just beaten by a better team. We were completely outplayed in every department.
We were given a footballing lesson. And Xavi was the professor.”
Prof. Dollar retweeted
1/ $QURE Guggenheim transcript from today's presentation.
As always, this is a fast draft transcript created from iPhone recording turned into raw transcript run through ChatGPT. THERE ARE MOST LIKELY TYPOS. I have not read it yet.
Prof. Dollar retweeted
$QURE: Useful commercial detail in Guggenheim’s Nov. 2 “Top Pick” note:
-Physician checks identify ~24 US sites with intraoperative MRI and ClearPoint capability. Guggenheim envisages ~25 treatments/month during the first six months after launch, rising toward ~50/month in the second six.
-The ~6,000 addressable symptomatic patients cited already account for striatal-volume requirements and some access barriers.
-The note references a $2.5–4.0m pricing range, although an actual launch price remains unconfirmed.
Guggenheim also views the planned AdCom as potentially constructive, expecting clinicians and patients to support AMT-130’s benefit–risk profile.
Prof. Dollar retweeted
If you watch one video today, it should be this.
@FDA_KyleD please rapidly speed up the review process for @uniQure_NV $QURE AMT130 for families like Heather's. Remove the unethical, unnecessary burden of the confirmatory trial by using currently treated patients along with following the first 100-150 commercially treated patients for confirmation.
Time Matters
@laurencurehd
@Christina4HD
@JRenz0418
@rachelreising96
@geneveritas
@SenRonJohnson
@SenRickScott
@RepAuchincloss
@houmanhemmati
@adamfeuerstein
@armstrongdrew
@l_e_whyte
@temple_west
@ScottGottliebMD
@BeckyQuick
@davidfaber
@AllysiaFinley
@bradloncar
@docrodwong
@LuckyPenguin10
@POTUS
@SenateAging
@SenBillCassidy
@SenRandPaul
@WhiteHouse
@FDACBER
@FDA_KyleD
@DrOzCMS
@HHSGov
#Duchenne
#PrimaryImmunodeficiency
#RareDisease
#HuntingtonsDisease
#FDA #PatientAdvocacy
#PatientVoice
#TimeMatters
#RareDiseaseResearch
#RareDiseaseFramework
@RickSantorum
@FoxNews
@bariweiss
@60Minutes
@CNBC
@WSJopinion
@WSJ
@statnews
Prof. Dollar retweeted
Replying to @FDA
CNPV for AMT-130. Every single day untreated for Huntingtons patients brings harm they can never reverse. The 4 month difference between AA and CNPV evaluation could be the difference for hundreds between being able to recieve lifesaving treatment or being too far gone to help.
Prof. Dollar retweeted
Sorry to add to the bad news today…
Novartis $NVS cites cases of previously unknown tumors possibly tied to its SMA gene therapy statnews.com/2026/11/05/nova… via @Jasonmmast @pharmalot
Prof. Dollar retweeted
$RARE is an example of recent gene therapy approval from August 2026 without the need for a real placebo-controlled trial and is instead using data from commercially treated patients. @FDA_KyleD please change the alignment with @uniQure_NV $QURE AMT130 to a similar design.
It will be unethical to follow HD patients for 3 years who never receive treatment until after the 3 years.
@laurencurehd
@Christina4HD
@JRenz0418
@rachelreising96
@geneveritas
@SenRonJohnson
@SenRickScott
@RepAuchincloss
@houmanhemmati
@adamfeuerstein
@armstrongdrew
@l_e_whyte
@temple_west
@ScottGottliebMD
@BeckyQuick
@davidfaber
@AllysiaFinley
@bradloncar
@docrodwong
@LuckyPenguin10
@POTUS
@SenateAging
@SenBillCassidy
@SenRandPaul
@WhiteHouse
@SusieWiles
@FDACBER
@FDA_KyleD
@DrOzCMS
@HHSGov
#Duchenne
#PrimaryImmunodeficiency
#RareDisease
#HuntingtonsDisease
#FDA #PatientAdvocacy
#PatientVoice
#TimeMatters
#RareDiseaseResearch
#RareDiseaseFramework
Prof. Dollar retweeted
$QURE We are now in the commercial launch chapter of the company. Time to start modelling what amt-130 is worth as a franchise.
1. Already talking to payers, there is ‘strong interest’. Already engaged NICE, NHS in England.
Prof. Dollar retweeted
Please help @Christina4HD and everyone else suffering from HD by making the BLA review process even faster than priority review of 6 months. @FDA_KyleD please speed up the PDUFA date for @uniQure_NV $QURE AMT130 more in line with the goal of the CNPV program, roughly 2 months from now.
Please don't make them wait any longer than they already have. Also, use flexibility in the design of the confirmatory study. There is no need for a new trial, you can use existing and growing data from the 51 patients already treated upwards of 5+ years ago utilizing this gene therapy and follow the first 100 or so patients who get treated after approval. There are already decades of natural history data to compare efficacy to. Make it happen, for the patients.
@SenRonJohnson
@SenRickScott
@RepAuchincloss
@houmanhemmati
@adamfeuerstein
@armstrongdrew
@l_e_whyte
@temple_west
@laurencurehd
@JRenz0418
@rachelreising96
@geneveritas
@ScottGottliebMD
@BeckyQuick
@davidfaber
@AllysiaFinley
@bradloncar
@docrodwong
@LuckyPenguin10
@POTUS
@SenateAging
@SenBillCassidy
@SenRandPaul
@WhiteHouse
@SusieWiles
@FDACBER
@FDA_KyleD
@DrOzCMS
@HHSGov
#Duchenne
#PrimaryImmunodeficiency
#RareDisease
#HuntingtonsDisease
#FDA #PatientAdvocacy
#PatientVoice
#TimeMatters
#RareDiseaseResearch
#RareDiseaseFramework
@RickSantorum
@FoxNews
@bariweiss
@60Minutes
@CNBC
@WSJopinion
@WSJ
@statnews
Today, the @FDA granted Priority Review to @uniQure_NV AMT-130, bringing the first potential disease-modifying therapy for Huntington’s disease one step closer to patients.
I learned this news while my father lay in the ICU, on a ventilator, with aspiration-related pneumonia.
Pneumonia is the leading cause of death in Huntington’s disease. My father is now confronting one of the very complications that make this disease so devastating.
That is what the irreversible cost of waiting looks like.
A few years ago, he was still running the business he built over 30 years ago. An accomplished businessman, inventor, and published author. Today, Huntington’s disease has taken his independence, his ability to swallow, much of his ability to communicate, and now threatens his life.
My grandmother was diagnosed with HD in 1999. She died in 2011. Twenty-seven years after her diagnosis, we still have no FDA-approved treatment that slows this devastating disease.
As a little girl, I watched HD take my grandmother. Today, my daughter, named in her honor, is watching the same disease take her grandfather and great-aunt.
I am profoundly grateful for today's milestone. But I cannot ignore the human cost of getting here.
I welcome the FDA's decision to grant Priority Review to AMT-130 and strongly support its consideration under the Accelerated Approval pathway. Our community has contributed decades of natural-history research, patient-experience data, and evidence of our willingness to accept meaningful risk.
Every day of delay carries consequences that no subsequent approval can undo.
Years ago, my father asked me, “Christina, what are you doing to leave the world a better place?”
Dad, this is my answer.
I'm fighting for you, for our family, for the more than 41,000 Americans living with Huntington’s disease, and the 200,000+ at risk of inheriting it.
I'm fighting for a future where my daughter never has to stand before the FDA, pleading for a treatment to save her mother, her brother, her aunts, or another generation of our family.
I want her to inherit my grandmother's name.
Not her fate. And certainly not this fight.
💙💜
#HuntingtonsDisease
#RareDisease
#CureHD
Prof. Dollar retweeted
While I'm excited about today's announcement from uniQure, I have very mixed emotions.
I believe AMT-130 works. I believe in its potential to change the future of Huntington's disease. But the road to this point has been an emotional roller coaster for our community, and we're still nowhere near the finish line.
I've lost count of how many advocates and families have asked me, "Why is it so hard for us to get this treatment?"
And the heartbreaking part is that I don't have an answer. Because it shouldn't be this hard.
I'm relieved that the FDA has finally accepted the application for Priority Review, and I welcome the opportunity for an Advisory Committee to examine the evidence and hear directly from patients and families.
However, I still have serious concerns about the proposed confirmatory trial, which I plan to address separately.
We are not asking for shortcuts. We are asking for a regulatory pathway that recognizes the reality of a relentlessly progressive disease and the human cost of every delay.
I'm also deeply disappointed by uniQure's communication with the very community that has fought so hard to get us here. Patients and families deserve transparency, consistency, and respect throughout this process.
But despite all the frustration, today is a step in the right direction.
And as I've said before, we have to allow ourselves to celebrate the wins along the way.
So today, I'll celebrate this progress. Tomorrow, I'll get back up, dust myself off, and continue fighting.
Because progress deserves to be celebrated, but our fight is far from over.
And until we have meaningful treatments available to the people who desperately need them, we cannot afford to stop.
#HuntingtonsDisease #raredisease #TimeMatters #ProgressionDoesntPause
@FDA_KyleD @FDA @FDADrugs @uniQure_NV
"uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of #HuntingtonsDisease" Check out the full press release on the Huntington's Post! #HDResearch
help4hd.org/post/uniqure-ann…
Prof. Dollar retweeted
For who did not/could not watch **Rare Disease Framework Initiative Hybrid Public Meeting**
October 28, 2026 #HD, #RareDisease
@laurencurehd @Christina4HD $qure
Prof. Dollar retweeted
I was blessed with the opportunity to speak today at this event. I have the utmost respect for the current FDA administration. You can see and feel how genuine they are, how dedicated they are to this new Rare Disease Framework Initiative. This is some exciting stuff!
Today, FDA kicked off its Rare Disease Framework Initiative with a public meeting, co-hosted by @ReaganUdall. Thanks to all who joined for your input, candor & vision. With only 5% of rare diseases having an approved treatment, the status quo isn't enough — we must do more.
FDA Acting Commissioner @FDA_KyleD shared with the attendees that the “urgency of the need has not changed, but now we — the agency, drug developers, researchers, and patients — are ready to meet that need together.”
Prof. Dollar retweeted
Replying to @FDA_KyleD
Replying to @laurencurehd
Thank you, Lauren, for representing our community at such a defining moment. Speak with uncompromising conviction. The consequences of regulatory decisions extend far beyond policy and precedent; they determine the futures of entire families. We have watched generations succumb to Huntington’s disease. Now, for the first time, science offers the possibility of changing that trajectory. The urgency of our lives deserves to be reflected in the urgency of the decisions that shape them. 💙💜
Prof. Dollar retweeted
Replying to @uniQure_NV
@uniQure_NV @ #ESGCT2026 in Hamburg!
The @ESGCT 33rd Annual Congress takes place in Hamburg, Germany, from 27-30 October 2026.
esgctcongress.com/poster-lis…
$QURE






































